Nishant Patel1, Adam C Yopp2, Amit G Singal3. 1. From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas. 2. From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas. From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas. 3. From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas. From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas. From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas.
Abstract
BACKGROUND: Most patients with hepatocellular carcinoma (HCC) present at advanced stages. The prevalence and clinical impact of delays during diagnostic evaluation among patients with HCC is unclear. PURPOSE: To identify and characterize factors associated with diagnostic delays among patients with HCC. METHODS: Records were reviewed for consecutive patients with cirrhosis and HCC at a large urban hospital between January 2005 and July 2012. Time from presentation to diagnosis was determined using Kaplan-Meier analysis. Diagnostic delay was defined as time to diagnosis exceeding 3 months, and multivariate logistic regression was used to identify correlates of diagnostic delays. RESULTS: Among 457 patients with HCC, 226 (49.5%) were diagnosed as outpatients. Among these, median time-to-diagnosis was 2.2 months, with 87 patients (38.5%) experiencing a diagnostic delay. Diagnostic delays were positively associated with the presence of hepatic encephalopathy (odds ratio [OR], 2.29; 95% CI, 1.03-5.07) and negatively associated with presentation after implementation of the electronic medical records (EMR) (OR, 0.28; 95% CI, 0.15-0.52) and presentation with an abnormal ultrasound (OR, 0.36; 95% CI, 0.19-0.67) on multivariate analysis. Higher rates of diagnostic delays were observed among those with hepatic encephalopathy (56% vs 35%), whereas lower rates were seen in those who presented after EMR implementation (26% vs 60%) and those who presented with an abnormal ultrasound with or without an elevated alpha fetoprotein level (27% vs 50%). Among 49 patients with mass-forming HCC and diagnostic delay, 18% had interval tumor growth of 2 cm or greater. CONCLUSIONS: Nearly 20% of patients with HCC wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth.
BACKGROUND: Most patients with hepatocellular carcinoma (HCC) present at advanced stages. The prevalence and clinical impact of delays during diagnostic evaluation among patients with HCC is unclear. PURPOSE: To identify and characterize factors associated with diagnostic delays among patients with HCC. METHODS: Records were reviewed for consecutive patients with cirrhosis and HCC at a large urban hospital between January 2005 and July 2012. Time from presentation to diagnosis was determined using Kaplan-Meier analysis. Diagnostic delay was defined as time to diagnosis exceeding 3 months, and multivariate logistic regression was used to identify correlates of diagnostic delays. RESULTS: Among 457 patients with HCC, 226 (49.5%) were diagnosed as outpatients. Among these, median time-to-diagnosis was 2.2 months, with 87 patients (38.5%) experiencing a diagnostic delay. Diagnostic delays were positively associated with the presence of hepatic encephalopathy (odds ratio [OR], 2.29; 95% CI, 1.03-5.07) and negatively associated with presentation after implementation of the electronic medical records (EMR) (OR, 0.28; 95% CI, 0.15-0.52) and presentation with an abnormal ultrasound (OR, 0.36; 95% CI, 0.19-0.67) on multivariate analysis. Higher rates of diagnostic delays were observed among those with hepatic encephalopathy (56% vs 35%), whereas lower rates were seen in those who presented after EMR implementation (26% vs 60%) and those who presented with an abnormal ultrasound with or without an elevated alpha fetoprotein level (27% vs 50%). Among 49 patients with mass-forming HCC and diagnostic delay, 18% had interval tumor growth of 2 cm or greater. CONCLUSIONS: Nearly 20% of patients with HCC wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth.
Authors: Amit G Singal; Adam Yopp; Celette S Skinner; Milton Packer; William M Lee; Jasmin A Tiro Journal: J Gen Intern Med Date: 2012-01-04 Impact factor: 5.128
Authors: Jessica A Davila; Robert O Morgan; Peter A Richardson; Xianglin L Du; Katherine A McGlynn; Hashem B El-Serag Journal: Hepatology Date: 2010-07 Impact factor: 17.425
Authors: Amit G Singal; Michael L Volk; Mina O Rakoski; Sherry Fu; Grace L Su; Heather McCurdy; Jorge A Marrero Journal: J Clin Gastroenterol Date: 2011-09 Impact factor: 3.062
Authors: Adam C Yopp; John C Mansour; Muhammad S Beg; Juan Arenas; Clayton Trimmer; Mark Reddick; Ivan Pedrosa; Gaurav Khatri; Takeshi Yakoo; Jeffrey J Meyer; Jacqueline Shaw; Jorge A Marrero; Amit G Singal Journal: Ann Surg Oncol Date: 2013-12-07 Impact factor: 5.344
Authors: Purva Gopal; Adam C Yopp; Akbar K Waljee; Jason Chiang; Mahendra Nehra; Pragathi Kandunoori; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2013-10-02 Impact factor: 11.382
Authors: Amit G Singal; Adam C Yopp; Samir Gupta; Celette Sugg Skinner; Ethan A Halm; Eucharia Okolo; Mahendra Nehra; William M Lee; Jorge A Marrero; Jasmin A Tiro Journal: Cancer Prev Res (Phila) Date: 2012-07-30
Authors: William A Stokes; Laura H Hendrix; Trevor J Royce; Ian M Allen; Paul A Godley; Andrew Z Wang; Ronald C Chen Journal: Cancer Date: 2013-05-28 Impact factor: 6.860
Authors: Nicole E Rich; Caitlin Hester; Mobolaji Odewole; Caitlin C Murphy; Neehar D Parikh; Jorge A Marrero; Adam C Yopp; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2018-05-31 Impact factor: 11.382
Authors: Omair Atiq; Jasmin Tiro; Adam C Yopp; Adam Muffler; Jorge A Marrero; Neehar D Parikh; Caitlin Murphy; Katharine McCallister; Amit G Singal Journal: Hepatology Date: 2016-12-19 Impact factor: 17.425
Authors: Amit G Singal; Jasmin A Tiro; Caitlin C Murphy; Jorge A Marrero; Katharine McCallister; Hannah Fullington; Caroline Mejias; Akbar K Waljee; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm Journal: Hepatology Date: 2018-12-14 Impact factor: 17.425
Authors: Amit G Singal; Jasmin A Tiro; Jorge A Marrero; Katharine McCallister; Caroline Mejias; Brian Adamson; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm Journal: Gastroenterology Date: 2016-11-05 Impact factor: 22.682
Authors: Joshua P Kronenfeld; Emily L Ryon; David Goldberg; Rachel M Lee; Adam Yopp; Annie Wang; Ann Y Lee; Sommer Luu; Cary Hsu; Eric Silberfein; Maria C Russell; Alan S Livingstone; Nipun B Merchant; Neha Goel Journal: Ann Surg Oncol Date: 2020-09-25 Impact factor: 5.344
Authors: Amit G Singal; Anna S Lok; Ziding Feng; Fasiha Kanwal; Neehar D Parikh Journal: Clin Gastroenterol Hepatol Date: 2020-09-19 Impact factor: 11.382